Clinical implications of the mechanism of action of antimicrobial agents.
D000900:Anti-Bacterial Agents / Q000037:antagonists & inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000890:Anti-Infective Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001414:Bacitracin / Q000494:pharmacology; D002462:Cell Membrane / Q000187:drug effects; D002473:Cell Wall / Q000187:drug effects; D002511:Cephalosporins / Q000494:pharmacology; D002701:Chloramphenicol / Q000494:pharmacology; D003523:Cycloserine / Q000494:pharmacology; D004357:Drug Synergism; D004917:Erythromycin / Q000494:pharmacology; D006801:Humans; D009268:Nalidixic Acid / Q000494:pharmacology; D009675:Novobiocin / Q000494:pharmacology; D009696:Nucleic Acids / Q000096:biosynthesis; D010403:Penicillin Resistance; D010406:Penicillins / Q000494:pharmacology; D014176:Protein Biosynthesis; D012293:Rifampin / Q000494:pharmacology; D012310:Ristocetin / Q000494:pharmacology; D013449:Sulfonamides / Q000494:pharmacology; D013752:Tetracycline / Q000494:pharmacology; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D000890:Anti-Infective Agents; D002511:Cephalosporins; D009696:Nucleic Acids; D010406:Penicillins; D013449:Sulfonamides; D012310:Ristocetin; D001414:Bacitracin; D009675:Novobiocin; D009268:Nalidixic Acid; D004917:Erythromycin; D002701:Chloramphenicol; D014640:Vancomycin; D003523:Cycloserine; D013752:Tetracycline; D012293:Rifampin